Search Results - "SPARANO, J"

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 by Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F.L., Penault-Llorca, F., Perez, E.A., Thompson, E.A., Symmans, W.F., Richardson, A.L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., Sparano, J., Kos, Z., Nielsen, T., Rimm, D.L., Allison, K.H., Reis-Filho, J.S., Loibl, S., Sotiriou, C., Viale, G., Badve, S., Adams, S., Willard-Gallo, K., Loi, S.

“…Evidence is strengthening for the morphological evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer. Herein, the concepts for TILs assessment…”
Get full text

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Loibl, S, André, F, Bachelot, T, Barrios, C H, Bergh, J, Burstein, H J, Cardoso, M J, Carey, L A, Dawood, S, Del Mastro, L, Denkert, C, Fallenberg, E M, Francis, P A, Gamal-Eldin, H, Gelmon, K, Geyer, C E, Gnant, M, Guarneri, V, Gupta, S, Kim, S B, Krug, D, Martin, M, Meattini, I, Morrow, M, Janni, W, Paluch-Shimon, S, Partridge, A, Poortmans, P, Pusztai, L, Regan, M M, Sparano, J, Spanic, T, Swain, S, Tjulandin, S, Toi, M, Trapani, D, Tutt, A, Xu, B, Curigliano, G, Harbeck, N

Get more information

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust by Piccart, M.J., Kalinsky, K., Gray, R., Barlow, W.E., Poncet, C., Cardoso, F., Winer, E., Sparano, J.

Get full text

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo by Ramaswamy, B., Fiskus, W., Cohen, B., Pellegrino, C., Hershman, D. L., Chuang, E., Luu, Thehang, Somlo, G., Goetz, M., Swaby, R., Shapiro, C. L., Stearns, V., Christos, P., Espinoza-Delgado, I., Bhalla, K., Sparano, J. A.

“…In preclinical models, the histone deacetylase inhibitor vorinostat sensitizes breast cancer cells to tubulin-polymerizing agents and to anti-vascular…”
Get full text

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification by Trapani, D., Franzoi, M.A., Burstein, H.J., Carey, L.A., Delaloge, S., Harbeck, N., Hayes, D.F., Kalinsky, K., Pusztai, L., Regan, M.M., Sestak, I., Spanic, T., Sparano, J., Jezdic, S., Cherny, N., Curigliano, G., Andre, F.

“…The landscape of clinical trials testing risk-adapted modulations of cancer treatments is complex. Multiple trial designs, endpoints, and thresholds for…”
Get full text

Erratum to “Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust”: [Annals of Oncology 32 (2021) 1077–1082] by Piccart, M.J., Kalinsky, K., Gray, R., Barlow, W.E., Poncet, C., Cardoso, F., Winer, E., Sparano, J.

Get full text

Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer by Chadha, M., White, J., Swain, S. M., Rakovitch, E., Jagsi, R., Whelan, T., Sparano, J. A.

“…Older women are under-represented in breast cancer (BC) clinical trials, and treatment guidelines are primarily based on BC studies in younger women. Studies…”
Get full text

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies by Rakovitch, E., Gray, R., Baehner, F. L., Sutradhar, R., Crager, M., Gu, S., Nofech-Mozes, S., Badve, S. S., Hanna, W., Hughes, L. L., Wood, W. C., Davidson, N. E., Paszat, L., Shak, S., Sparano, J. A., Solin, L. J.

“…Purpose Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The DCIS score (DS) was validated as a…”
Get full text

Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma by Barta, S.K., Samuel, M.S., Xue, X., Wang, D., Lee, J.Y., Mounier, N., Ribera, J.-M., Spina, M., Tirelli, U., Weiss, R., Galicier, L., Boue, F., Little, R.F., Dunleavy, K., Wilson, W.H., Wyen, C., Remick, S.C., Kaplan, L.D., Ratner, L., Noy, A., Sparano, J.A.

“…Patients with the most common aggressive AIDS-related non-Hodgkin lymphomas can expect improved outcomes approaching those of immunocompetent patients in the…”
Get full text

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 by Schneider, B P, Li, L, Shen, F, Miller, K D, Radovich, M, O'Neill, A, Gray, R J, Lane, D, Flockhart, D A, Jiang, G, Wang, Z, Lai, D, Koller, D, Pratt, J H, Dang, C T, Northfelt, D, Perez, E A, Shenkier, T, Cobleigh, M, Smith, M L, Railey, E, Partridge, A, Gralow, J, Sparano, J, Davidson, N E, Foroud, T, Sledge, G W

“…Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting…”
Get full text

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast by SOLIN, Lawrence J, GRAY, Robert, DAVIDSON, Nancy E, INGLE, James N, PEREZ, Edith A, WOOD, William C, SPARANO, Joseph A, BADVE, Sunil, BAEHNER, Frederick L, BUTLER, Steven M, HUGHES, Lorie L, YOSHIZAWA, Carl, CHERBAVAZ, Diana B, SHAK, Steven, PAGE, David L, SLEDGE, George W

“…For women with ductal carcinoma in situ (DCIS) of the breast, the risk of developing an ipsilateral breast event (IBE; defined as local recurrence of DCIS or…”
Get full text

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial by Kalinsky, K., Sparano, J. A., Zhong, X., Andreopoulou, E., Taback, B., Wiechmann, L., Feldman, S. M., Ananthakrishnan, P., Ahmad, A., Cremers, S., Sireci, A. N., Cross, J. R., Marks, D. K., Mundi, P., Connolly, E., Crew, K. D., Maurer, M. A., Hibshoosh, H., Lee, S., Hershman, D. L.

“…Introduction The PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects…”
Get full text

Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045) by Garg, M.K, Zhao, F, Lee, J, Sparano, J, Palefsky, J, Henry, D, Wachsman, W, Rajdev, L, Aboulafia, D, Mitchell, E, Onitilo, A, El-Rayes, B, Nabbout, N, Fitzgerald, T, Mitsuyasu, R, Benson, A.B, Kachnic, L.A

Get full text

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205 by Li, T., Christos, P. J., Sparano, J. A., Hershman, D. L., Hoschander, S., O'Brien, K., Wright, J. J., Vahdat, L. T.

“…Background: Fulvestrant produces a clinical benefit rate (CBR) of ∼45% in tamoxifen-resistant, hormone receptor (HR)-positive metastatic breast cancer (MBC)…”
Get full text

Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary by Chuang, E., Wiener, N., Christos, P., Kessler, R., Cobham, M., Donovan, D., Goldberg, G.L., Caputo, T., Doyle, A., Vahdat, L., Sparano, J.A.

“…Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with…”
Get full text

5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry by Sparano, J, Gray, R, Zujewski, J.A, Makower, D, Pritchard, K, Albain, K, Hayes, D, Geyer, C, Dees, C, Perez, E, Keane, M, Vallejos, C, Goggins, T, Mayer, I, Brufsky, A, Toppmeyer, D, Kaklamani, V, Atkins, J, Olson, J, Sledge, G

Get full text

MC13-0019 Tumor microenvironment of metastasis: An imaging based marker of risk for distant metastasis of breast cancer by Jones, J, Xue, X, Lin, H, Oktay, M, Robinson, B, Gertler, F, Glass, A, Sparano, J, Condeelis, J, Rohan, T

Get full text

Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics by Sparano, J A

“…Doxorubicin and the taxanes, paclitaxel and docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA), are among the most active cytotoxic agents for the…”
Get more information

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer by Miller, K. D., Gradishar, W., Schuchter, L., Sparano, J. A., Cobleigh, M., Robert, N., Rasmussen, H., Sledge, G. W.

“…Background: This pilot trial was performed to evaluate the safety, toxicity and pharmacokinetics of chronic therapy with the matrix metalloproteinase inhibitor…”
Get full text

Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers by Pothuri, B, Sparano, J, Blank, S, Curtin, J, Chuang, E, Hershman, D, Tiersten, A, Liebes, L, Chen, A, Muggia, F

Get full text